Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TYRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTyra Biosciences completes routine annual meeting, elects three directors for 2026-2029 term
Filed June 2, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
low
Three Class II directors elected to three-year terms expiring 2029: Habib J. Dable, Susan Moran M.D., and Robert More, all receiving strong shareholder support with 41-44.5 million votes in favor.
Item 5.07 verify on EDGAR → -
low
Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2026 with overwhelming approval (53 million votes for, minimal opposition).
Item 5.07 verify on EDGAR →
Summary
Tyra Biosciences held its 2026 Annual Meeting on May 28, completing standard corporate governance procedures. The company elected three Class II directors to serve through 2029 and ratified its auditor selection, both with strong shareholder backing. All three director nominees—Habib J. Dable, Susan Moran, and Robert More—received substantial support, indicating no governance controversies or shareholder dissent.
For retail investors, this filing represents routine annual business with no material impact on operations, strategy, or financial outlook. The strong voting results suggest stable board oversight and shareholder confidence in management. Watch for the company's upcoming quarterly earnings report or pipeline updates for information that could materially affect investment decisions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify